Xometry
Xometry's revenue rose 25.9% to $687 million in fiscal 2025. Its operating margin was −6.6%, up from −10.3% a year earlier. Free cash flow was −$24 million. It paid out $8 million in dividends and buybacks.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Xometry lost money in fiscal 2025: a net loss of $62 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 117 | 319 | 269 | 240 | 219 |
| Debt incl. finance leases | — | 280 | 282 | 284 | 328 |
| Net debt (negative means net cash) | — | −40 | 13 | 44 | 108 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.8x | 0.9x | 0.9x | 1.2x |
| Interest coverage | −68.9x | −17.4x | −15.4x | −11.8x | −9.3x |
| Current ratio | 2.9x | 6.0x | 4.3x | 4.4x | 3.8x |
| Quick ratio | 2.8x | 6.0x | 4.2x | 4.3x | 3.7x |
Cash flow
Projections
Project Xometry's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $4.0 million of Xometry shares on the open market, and 8 insiders sold $19.3 million, $12.6 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Sanjeev Singh SahniChief Executive Officer, Director | Sold plan | 1,500 | $85.23 | $127,842 | Form 4 |
| Sep 1, 2026 | Randolph AltschulerDirector | Sold plan | 10,000 | $90.82 | $908,230 | Form 4 |
| Aug 31, 2026 | Katharine WeymouthDirector | Sold | 5,000 | $95.23 | $476,150 | Form 4 |
| Aug 28, 2026 | Katharine WeymouthDirector | Sold | 5,000 | $94.30 | $471,500 | Form 4 |
| Aug 27, 2026 | Vaidyanathan RaghavanChief Technology Officer | Sold | 5,000 | $96.77 | $483,850 | Form 4 |
| Aug 19, 2026 | Emily RollinsDirector | Sold plan | 5,000 | $84.31 | $421,543 | Form 4 |
| Aug 17, 2026 | Sanjeev Singh SahniChief Executive Officer, Director | Sold plan | 1,500 | $90.19 | $135,278 | Form 4 |
| Aug 11, 2026 | Fabio RosatiDirector | Sold | 1,900 | $89.72 | $170,468 | Form 4 |
| Aug 10, 2026 | Fabio RosatiDirector | Sold | 8,100 | $91.45 | $740,723 | Form 4 |
| Aug 6, 2026 | James MilnChief Financial Officer | Sold plan | 1,500 | $87.92 | $131,878 | Form 4 |
| Jul 2, 2026 | Randolph AltschulerDirector | Sold plan | 5,722 | $93.30 | $533,866 | Form 4 |
| Jul 2, 2026 | James MilnChief Financial Officer | Sold plan | 2,392 | $93.29 | $223,149 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 5 of 9 | — |
| Rule of 40 | 11.2% | 11.6% | 22.4% |
| Altman Z'' | 1.28 | 1.02 | 0.54 |
| Accruals ratio | −5.2% | −5.0% | −9.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | — |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 4 of 9 | 5 of 9 | — |
Compare
Put Xometry side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Xometry | FY25 | 25.9% | −6.6% | −3.5% | −9.7% | — | — | |
| Civeo | FY25 | −6.3% | 0.6% | 0.3% | 1.0% | 2.2x | 6 | Compare |
| Liquidity Services | FY26 | 0.3% | 10.2% | 10.2% | — | — | — | Compare |
| Resolute Holdings | FY25 | 9.9% | 31.0% | 41.0% | 197.0% | −0.1x | — | Compare |
| Transcat | FY26 | 19.2% | 4.0% | 5.9% | 2.5% | 2.4x | 5 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 80 | 141 | 218 | 381 | 463 | 546 | 687 |
| Revenue growth | — | 76.3% | 54.4% | 74.5% | 21.6% | 17.7% | 25.9% |
| Gross profit | 15 | 33 | 57 | 146 | 178 | 216 | 269 |
| Research and development | 11 | 12 | 18 | 31 | 34 | 39 | 47 |
| Operating income | −30 | −29 | −59 | −77 | −74 | −56 | −46 |
| Net income | −31 | −31 | −61 | −79 | −68 | −50 | −62 |
| Diluted EPS (US$) | −4.88 | −5.32 | −2.33 | −1.68 | −1.41 | −1.03 | — |
| Diluted shares (millions) | 6 | 8 | 26 | 47 | 48 | 49 | — |
| Cash flow | |||||||
| Cash from operations | −27 | −22 | −69 | −63 | −30 | −15 | 6 |
| Capital expenditure | 3 | 4 | 6 | 14 | 18 | 18 | 30 |
| Free cash flow | −30 | −26 | −75 | −76 | −48 | −33 | −24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Acquisitions | 1 | 0 | 175 | 0 | 3 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 7 | 19 | 22 | 29 | 36 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | — | 60 | 117 | 319 | 269 | 240 | 219 |
| Debt incl. finance leases | — | — | — | 280 | 282 | 284 | 328 |
| Total assets | — | 89 | 503 | 734 | 707 | 680 | 704 |
| Total liabilities | — | 40 | 77 | 362 | 377 | 364 | 427 |
| Shareholders' equity | −73 | −111 | 424 | 371 | 329 | 314 | 276 |
| Margins and ratios | |||||||
| Gross margin | 18.4% | 23.5% | 26.2% | 38.3% | 38.5% | 39.5% | 39.1% |
| Operating margin | −38.1% | −20.7% | −26.9% | −20.2% | −15.9% | −10.3% | −6.6% |
| Net margin | −38.6% | −22.0% | −28.1% | −20.8% | −14.6% | −9.2% | −9.0% |
| Free cash flow margin | −37.2% | −18.6% | −34.3% | −20.0% | −10.4% | −6.1% | −3.5% |
| Rule of 40 (growth + FCF margin) | — | 57.7% | 20.1% | 54.5% | 11.2% | 11.6% | 22.4% |
| Return on capital | — | — | — | — | −17.2% | −12.6% | −9.7% |
| Return on equity | — | — | −39.2% | −19.9% | −19.3% | −15.7% | −20.9% |
| Return on assets | — | — | −20.8% | −12.8% | −9.4% | −7.3% | −8.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — |